Article originally posted at GenomeWeb

Deep Genomics announced today that it has received a $13 million equity investment.

The financing was led by Khosla Ventures and included True Ventures, and follows a $3.7 million seed financing round for Deep Genomics in 2015.

The Toronto-based company is developing a bioinformatics platform called Saturn that searches billions of molecules to generate a library of compounds that can precisely manipulate cell biology. The company aims to use the platform to identify preclinical candidates, including new classes of antisense oligonucleotides, for clinical evaluation with collaborators.

“We believe that the technology developed at Deep Genomics puts them in a unique position to identify new…”

Read the entire article.